Hansa Biopharma

The company focuses on rare autoimmune diseases in which IgG antibodies play a significant role, including Guillain-Barré syndrome (GBS) and anti-glomerular basement membrane (anti-GBM).

The company develops solutions to enable gene therapy in patients with anti-AAV antibodies by creating an IgG-free window.

Imlifidase is a unique antibody-cleaving enzyme that specifically targets IgG and inhibits IgG-mediated immune response within hours.

Hansa’s proprietary enzymes, imlifidase and HNSA-5487, inactivate IgG antibodies in the blood and tissues, inhibiting the IgG-mediated immune responses.

Ron, Anti-GBM patient and kidney recipient, The Netherlands

Highly sensitized patients account for approximately 10-15 percent1,2 of the patients on the transplant waiting lists in the US and Europe. Due to their immunological profiles, they face prolonged – often indefinite– waiting times on waiting lists and disproportionately high mortality.3,4

The immune status of highly sensitized patients makes it harder to find an immunologically suitable donor, and they tend to spend a significantly longer time on organ waiting lists having a lower chance of ever receiving a potentially lifesaving kidney transplant.

Hansa Biopharma publishes annual and sustainability reports.

Lund, Sweden, 21 March 2025. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.

Hansa says its teams are results driven and have a strong sense of purpose.

Hansa says its teams are results-oriented and guided by a strong sense of purpose.

Report adverse effects, product complaints, and submit medical inquiries related to Hansa Biopharma's product.

The company develops treatments for patients with rare immunologic conditions, with the aim of helping them live longer and healthier lives.